Lv31
310 积分 2025-08-17 加入
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study
11小时前
待确认
Circulating proteins associated with histological subtypes of lung cancer from genetic and population-based perspectives
11天前
已完结
scRNA-seq reveals that VEGF signaling mediates the response to neoadjuvant anlotinib combined with PD-1 blockade therapy in non-small cell lung cancer
27天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
1个月前
已完结
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing
1个月前
已完结
Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project
1个月前
已完结
Prognostic Impact of ALK Rearrangements in Resected NSCLC: A Systematic Review and Meta-analysis
1个月前
已完结
Management of Patients With Early-Stage Non-Small Cell Lung Cancer
1个月前
已完结
Efficacy and safety of ensartinib in the treatment of non-small cell lung cancer: A systematic review of clinical trials
1个月前
已完结
皖公网安备34019202002308
